drugset
drugset / Trial / NCT05436912

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

NCT05436912 ↗

Phase 1 Completed 36 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to assess how selpercatinib gets into the blood stream and how long it takes the body to remove it when administered to participants with impaired hepatic function compared to healthy participants. Information about safety and tolerability will be collected. The study will last up to about 7 weeks, inclusive of screening period.

Timeline

Start
2018-12-10
Primary completion
2019-10-04
Completion
2019-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Selpercatinib Small molecule 160 mg Oral

Indications

No indication recorded.